TaiGen Biotechnology Co., Ltd. was established in Taiwan in 2001 by a professional team of American and Taiwanese specialists with 30 years experience in this field. In 2005, a subsidiary was founded in Beijing. The pharmaceutical research company focuses on R&D and is product oriented.
TaiGen has a global focus, researches and develops new superior pharmaceutical products that stand out from those of its competitors through the company's own research capability and the authorized use of external resources. The company pays special attention to areas of high market demand and the most prevalent diseases such as infectious diseases, cancer, and diabetes complications.
There are currently three medications that have reached the clinical trial stage, namely Nemonoacin (type 1.1) and TG-0054, which have reached the third and second stages of clinical trials, respectively, and a new medication for the treatment of hepatitis C.TaiGen Biotechnology